Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence

2024-9-12

Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia

2024-9-11

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation

2024-9-7

Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma

2024-9-6

Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity

2024-9-3

Correction to: Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

2024-8-31

Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections

2024-8-22

Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors

2024-8-19

Machine Learning Methods for Precision Dosing in Anticancer Drug Therapy: A Scoping Review

2024-8-17

Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease

2024-8-15

Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool

2024-8-1

Antibiotics Removal during Continuous Renal Replacement Therapy in Septic Shock Patients: Mixed Modality Versus “Expanded Haemodialysis”

2024-8-1

Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours

2024-8-1

A Machine Learning Algorithm to Predict the Starting Dose of Daptomycin

2024-7-31

Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity

2024-7-29

Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

2024-7-26

Dosing Adjustments in Cases of Altered Plasma Protein Binding are Most Needed for Drugs with a Volume of Distribution Below 1.3 L/kg

2024-7-24

Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy

2024-7-20

Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation

2024-7-16

Can we Predict Drug Excretion into Saliva? A Systematic Review and Analysis of Physicochemical Properties

2024-7-15

Machine Learning Approach in Dosage Individualization of Isoniazid for Tuberculosis

2024-7-11

Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults

2024-7-2

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial

2024-7-1

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

2024-7-1

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial

2024-7-1

Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population

2024-7-1

Correction to: Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID‑19

2024-6-28

The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study

2024-6-28

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

2024-6-22

Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges

2024-6-18

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

2024-6-1

Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework

2024-6-1

Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective

2024-6-1

P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants

2024-6-1

Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens

2024-6-1

Dose-Response Study of Norepinephrine Infusion for Maternal Hypotension in Preeclamptic Patients Undergoing Cesarean Delivery Under Spinal Anesthesia

2024-6-1

Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug–drug Interactions

2024-5-31

Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population

2024-5-30

Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses

2024-5-28

Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients”

2024-5-11

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec

2024-5-9

Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review

2024-5-4

Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

2024-5-2

Drugs in Human Milk Part 1: Practical and Analytical Considerations in Measuring Drugs and Metabolites in Human Milk

2024-5-1

Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model

2024-4-23

Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents

2024-4-13

Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review

2024-4-7

Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration

2024-4-6

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

2024-4-5

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

2024-4-4